ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02901483
Recruitment Status : Recruiting
First Posted : September 15, 2016
Last Update Posted : August 31, 2018
Sponsor:
Information provided by (Responsible Party):
PharmaEngine

Brief Summary:

It's a prospective, open-label, single arm, nonrandomized study of PEP503 in head and neck squamous cell carcinoma (HNSCC) patients.

  • Escalation portion (Phase 1b):A 3 + 3 dose escalation study design will be adopted in this phase to identify the recommended intratumor injection volumes of PEP503.
  • Expansion portion (Phase 2): Following confirmation of the recommended volumes, 18 additional patients will be enrolled at the recommended volume level to evaluate for safety and efficacy.

Condition or disease Intervention/treatment Phase
Head and Neck Squamous Cell Carcinoma Drug: PEP503 Drug: Cisplatin Radiation: Radiotherapy Phase 1 Phase 2

Detailed Description:

Primary Objectives:

  • Phase 1b (dose escalation portion): To assess the safety profile and determine the Dose Limiting Toxicity (DLT) and to define the recommended volumes (doses) of PEP503.
  • Phase 2 (expansion portion): To evaluate the anti-tumor activity in terms of the rate of locoregional control at one year and to evaluate the safety profile.

Secondary Objectives:

  • Phase 1b: To characterize the body kinetic profile of PEP503.
  • Phase 2: Objective tumor response, progression free survival rate at 1 year and pathological response (pR).

The target population is composed by patients who have pathologically confirmed squamous cell carcinoma of oral cavity with disease clinically staged as T4b who are not candidates for surgical resection or T3-4 who decline surgery or medical inoperable, without metastasis disease. ECOG performance status 0 or 1 and adequate bone marrow, renal, and hepatic function.

Dose limiting toxicity (DLT) - The DLTs are related to PEP503, injection procedure, or concurrent chemo radiation therapy and occur in the DLT evaluation period. The DLT evaluation period starts from the intratumor injection of PEP503 to 4 weeks after the completion of radiation treatment.

There are 4 levels (Level 1, Level 2, Level 3 and Level 4 correspond to 5%, 10%, 15% and 22% of the total baseline tumor volume, respectively) in this phase 1b study. PEP503 will be given at the fixed concentration of 53.3g/L. The starting volume of PEP503 to be injected is 5% (Level 1) of the tumor volume confirmed by MRI.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 42 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b/2 Study of PEP503 (Radioenhancer) With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer
Actual Study Start Date : October 11, 2016
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Cisplatin

Arm Intervention/treatment
Experimental: PEP503+Cisplatin+Radiotheraphy

Phase 1b: There are 4 levels (5%, 10%, 15% and 22%) in this phase 1b study. Only primary tumor will receive PEP503 implementation via intratumor injection. A 3 + 3 dose escalation study design will be adopted in this phase to identify the recommended intratumor injection volumes of PEP503.

Phase 2: The recommended volume identified from phase 1b will be applied in phase 2 for both primary tumor and ≥ 3 cm lymph node lesions.

Drug: PEP503
PEP503 will be administered by intratumoral route as slow injection
Other Name: NBTXR3

Drug: Cisplatin
The concurrent chemoradiotherapy. Weekly cisplatin 40 mg/m2 with a minimum of accumulated 200 mg/m2 during the 7~8 weeks' radiation period.

Radiation: Radiotherapy
Patients will receive 70-72 Gy, 2-2.12 Gy/fraction over 7~8 weeks.




Primary Outcome Measures :
  1. Phase 1: Determination of the Recommended doses and the Dose Limiting Toxicities (DLT) [ Time Frame: 24 months ]
    To determine the Recommended volumes and the Dose Limiting Toxicities (DLT) of PEP503 administered as intratumor injection, activated by CCRT

  2. Phase 2: The rate of locoregional control at one year [ Time Frame: 24 months ]
    To evaluate the rate of locoregional control at one year after PEP503 intratumor injection

  3. Phase1 and 2: Evaluation of Safety profile of PEP503 [ Time Frame: 24 months ]
    Safety of PEP503, as intratumor injection schedule, activated by CCRT will be assessed in terms of incidence and severity of clinical and laboratory Adverse Events by NCI-CTCAE version 4.0


Secondary Outcome Measures :
  1. Phase 1: The body kinetic profile of PEP503 [ Time Frame: 24 months ]
    To characterize the body kinetics on Date of injection(DINJ) of PEP503 administered by intratumor injection before CCRT

  2. Phase 2: Evaluation of objective tumor response as per Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: 24 months ]
    To evaluate the objective tumor rate by using RECIST v1.1 after intratumor injection schedule, activated by CCRT

  3. Phase 2: Pathological response (pR) [ Time Frame: 24 months ]
    If patients receive tumor and/or neck lymph node dissection after treatment, to assess according to the evidence of viable tumor cell

  4. Phase 2: Evalution of progression free survival rate at 1 year [ Time Frame: 24 months ]
    To evaluate the progression free survival rate at 1 year after the intratumor injection of PEP503



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed squamous cell carcinoma (SCC) of oral cavity
  • Advanced or recurrent disease: T4b, N any, who are not candidates for surgical resection; or T3-4, N any, who decline surgery or medical inoperable
  • No evidence of distant metastatic disease, as determined by a negative PET scan or CT scan
  • ECOG Performance Status 0 or 1
  • Adequate function of bone marrow, kidney and liver:

    • White Blood Cell (WBC) ≥ 3.0 x 109/l
    • Absolute neutrophil count (ANC) ≥ 1.5 x 109/l
    • Platelet count ≥ 100 x 109/l
    • Hemoglobin ≥ 9.0 g/dL
    • Creatinine ≤ 1.5 x ULN
    • AST ≤ 2.5 x ULN, ALT ≤ 2.5 x ULN and Alkaline phosphatase (ALP) ≤ 2.5 x ULN
    • Bilirubin ≤ 1.5 x ULN
  • 20 years of age or older
  • All female patients of childbearing potential must have negative urine pregnancy test within 7 days prior to study treatment with PEP503. Fertile patients must agree to use effective contraception during the study

Exclusion Criteria:

  • Tumor ulceration combined with vascular risks
  • Prior radiotherapy to any area within the planned radiotherapy field
  • Uncontrolled intercurrent illness
  • Concurrent treatment with any other anticancer therapy
  • Participation in any investigational drug study within 4 weeks
  • Prior or concurrent non-head and neck malignancies, excluding adequately treated basal or squamous cell cancer of the skin, and in situ cervical cancer, and any other cancer from which the subject has been cancer free for 5 years
  • Patients unable to comply with scheduled visits and other study procedures.
  • Preexisting neuropathy ≥ 2
  • History of allergic reaction to platinum product

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02901483


Contacts
Contact: Weiche Yu +886 2 25158228 weiche.yu@pharmaengine.com

Locations
Taiwan
Keelung Chang Gung Memorial Hospital (Lovers Lake Branch) Recruiting
Keelung, Taiwan
Sponsors and Collaborators
PharmaEngine
Investigators
Principal Investigator: Cheng-Hsu Wang, M.D. Keelung Chang Gung Memeorial Hospital (Lovers Lake Branch)

Responsible Party: PharmaEngine
ClinicalTrials.gov Identifier: NCT02901483     History of Changes
Other Study ID Numbers: PEP503-HN-1002
First Posted: September 15, 2016    Key Record Dates
Last Update Posted: August 31, 2018
Last Verified: August 2018

Keywords provided by PharmaEngine:
Head and Neck

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Neoplasms by Site
Cisplatin
Antineoplastic Agents